SY2-3 - Long-term prognosis for ovarian cancer based on front-line chemotherapy ∼Is it the same for each histological type?

Abstract

Objectives: This study was conducted to examine the effect of the front-line chemotherapy on overall (OS) of patients with ovarian cancer (EOC) on stratifying the histological type.Materials and methods: 1723 patients with EOC with sufficient clinical information including chemotherapy were analyzed. The number of patients with each histological type was as follows, serous (S): 767, clear-cell (C): 469, endometrioid (E): 320, mucinous (M): 167. The pathological slides were evaluated under central pathological review. On stratifying by the 1st-line chemotherapy, we divided all patients into two groups: group A (N = 1094): patients who underwent taxane plus platinum and group B (N = 629): patients who underwent conventional platinum-based chemotherapy.Results: The median age was 54 (14-87). The 5-year OS/PFS rates for the two groups were as follows: group A: 64.3/48.3 months, group B: 51.0/41.7 months, respectively. The OS and PFS were significantly poorer in group B than group A {OS: P <0.0001, PFS: P = 0.0005}. Confining to analyses in stage III/IV patients (N = 676), the 5-year OS rate of each histological type was as follows (Group A/B), S: 41.8/29.8%, C: 44.4/32.9%, E: 53.2/44.3%, M: 23.4/22.7%. In advanced-stage patients with C/M histology, the OS did not significantly differ regardless of the type of chemotherapy. In contrast, among stage III/IV patients with the S/E histology, the indicators of group A were significantly better than those of group B (OS: P =0.0003). Multivariable analyses revealed that, among patients at stage III/IV with S/E histology, the type of chemotherapy was significantly independent prognostic indicators of a poorer OS [Group A/B (95%CI): HR: 0.689 (0.567-0.836), P = 0.0002]. Conversely, in those with a C/M histology, that did not influence the OS. Conclusions: Since the emergence of taxane plus platinum, the prognosis of patients with advanced EOC has improved. However, this improvement has been limited to those with a non-C/M histology. Objectives: This study was conducted to examine the effect of the front-line chemotherapy on overall (OS) of patients with ovarian cancer (EOC) on stratifying the histological type. Materials and methods: 1723 patients with EOC with sufficient clinical information including chemotherapy were analyzed. The number of patients with each histological type was as follows, serous (S): 767, clear-cell (C): 469, endometrioid (E): 320, mucinous (M): 167. The pathological slides were evaluated under central pathological review. On stratifying by the 1st-line chemotherapy, we divided all patients into two groups: group A (N = 1094): patients who underwent taxane plus platinum and group B (N = 629): patients who underwent conventional platinum-based chemotherapy. Results: The median age was 54 (14-87). The 5-year OS/PFS rates for the two groups were as follows: group A: 64.3/48.3 months, group B: 51.0/41.7 months, respectively. The OS and PFS were significantly poorer in group B than group A {OS: P <0.0001, PFS: P = 0.0005}. Confining to analyses in stage III/IV patients (N = 676), the 5-year OS rate of each histological type was as follows (Group A/B), S: 41.8/29.8%, C: 44.4/32.9%, E: 53.2/44.3%, M: 23.4/22.7%. In advanced-stage patients with C/M histology, the OS did not significantly differ regardless of the type of chemotherapy. In contrast, among stage III/IV patients with the S/E histology, the indicators of group A were significantly better than those of group B (OS: P =0.0003). Multivariable analyses revealed that, among patients at stage III/IV with S/E histology, the type of chemotherapy was significantly independent prognostic indicators of a poorer OS [Group A/B (95%CI): HR: 0.689 (0.567-0.836), P = 0.0002]. Conversely, in those with a C/M histology, that did not influence the OS. Conclusions: Since the emergence of taxane plus platinum, the prognosis of patients with advanced EOC has improved. However, this improvement has been limited to those with a non-C/M histology.